AMINOLOGICS CO.,LTD. Logo

AMINOLOGICS CO.,LTD.

Specialty manufacturer of high-purity chiral amino acids and their derivatives.

074430 | KO

Overview

Corporate Details

ISIN(s):
KR7074430000
LEI:
Country:
South Korea
Address:
서울특별시 강남구 역삼로 151 삼오빌딩3층 301호, 서울특별시

Description

AMINOLOGICS CO.,LTD. is a specialty manufacturer of amino acids and their derivatives. The company's core competency is its proprietary chiral resolution platform technology, ARCA (Alanine Racemase Chiral). This innovative enzymatic process enables the cost-effective production of a wide range of high-purity chiral amino acids. These products serve as essential building blocks and Active Pharmaceutical Ingredients (APIs) for various sectors, including the pharmaceutical, fine chemical, agrochemical, and life science industries. The technology allows for the development of new products and treatments by providing materials with high optical purity at a reduced cost.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-04 00:00
주식등의대량보유상황보고서(약식)
Korean 66.7 KB
2025-06-30 00:00
증권발행결과(자율공시)
Korean 5.6 KB
2025-06-26 00:00
주요사항보고서(전환사채권발행결정)
Korean 86.7 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 930.5 KB
2025-03-31 00:00
정기주주총회결과
Korean 22.1 KB
2025-03-21 00:00
감사보고서제출
Korean 24.8 KB
2025-03-21 00:00
사업보고서 (2024.12)
Korean 1.3 MB
2025-03-12 00:00
주주총회소집공고
Korean 157.5 KB
2025-03-10 00:00
의결권대리행사권유참고서류
Korean 138.0 KB
2025-02-28 00:00
주주총회소집결의
Korean 10.7 KB
2025-02-27 00:00
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.6 KB
2025-01-31 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.9 KB
2024-12-12 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-08 00:00
분기보고서 (2024.09)
Korean 944.5 KB

Automate Your Workflow. Get a real-time feed of all AMINOLOGICS CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AMINOLOGICS CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AMINOLOGICS CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.